Sales and Marketing

Showing 15 posts of 11526 posts found.

Cellnovo, Roche sign deal to integrate diabetes platforms

March 15, 2016 Manufacturing and Production, Sales and Marketing Cellnovo, Roche, diabetes

Cellnovo Group (Paris: CLNV) on Tuesday said it has signed a deal with Swiss drug major Roche (Euronext: ROG) to …
shutterstock_244903099

InVivo Therapeutics to sell stake in company; shares drop

March 15, 2016 Business Services, Manufacturing and Production, Research and Development, Sales and Marketing InVivo Therapeutics, Stake sale, stocks

InVivo Therapeutics (Nasdaq: NVIV) said it plans to sell an additional stake in the company to raise funds for its ongoing …
vascepa

COMMENT: What does Amarin’s off-patent victory over the FDA mean for the industry?

March 14, 2016 Medical Communications, Sales and Marketing Amarin, FDA, off label, off-label, vascepa

Last week, Pharmafile.com reported that small biopharma Amarin had settled litigation with US drugs regulator the FDA that will allow …
lab

Cambridge Epigenetix says raised $21 million, appoints Geoff Smith CEO

March 14, 2016 Business Services, Sales and Marketing CEGX, CEO, Cambridge Epigenetix, fundraising, genome sequencing

Cambridge Epigenetix (CEGX) on Monday said it has raised about $21 million via Series B financing and named Geoff Smith …
manmeetsoni

Ariad names Manmeet Soni CFO

March 14, 2016 Business Services, Sales and Marketing Ariad, CEO, appointment, boardroom, cfo

Ariad Pharmaceuticals Inc (Nasdaq: ARIA) named Manmeet Soni chief financial officer, effective March 21, 2016, succeeding Edward Fitzgerald. Mr Soni will …
janssen_latest_logo_on_sign_closer

Janssen’s Zytiga boosts survival in early-stage prostate cancer

March 14, 2016 Research and Development, Sales and Marketing Janssen, Zytiga, abiraterone, prednisone, prostate cancer

Janssen has announced data from a post-hoc analysis of a Phase III trial showing that Zytiga plus prednisone boosted overall …
xalkori

FDA approves Pfizer sNDA for Xalkori

March 14, 2016 Research and Development, Sales and Marketing Cancer, EMA, NSCLC, Pfizer, Xalkori (crizotinib)

The US FDA has approved Pfizer’s supplemental new drug application (sNDA) for its kinase inhibitor Xalkori in treating patients with …
gilead-sciences

EMA starts review of Gilead Sciences’ Zydelig following safety concerns

March 14, 2016 Research and Development, Sales and Marketing EMA, Gilead Sciences, blood cancer, clinical trials, zydelig

Regulators in Europe have initiated a safety review of Gilead Sciences’ (Nasdaq: GILD) blood cancer drug Zydelig (idelalisib) following reports …
five_prime_therapeutics_scientist

GSK terminates Five Prime Therapeutics mesothelioma collaboration

March 14, 2016 Research and Development, Sales and Marketing Five Prime Therapeutics, GSK, mesothelioma

GSK is to back out of a licensing deal with California-based Five Prime Therapeutics to develop a mesothelioma drug. Announcing …

Pfizer’s India unit stops production of cough drug, shares drop almost 8%

March 14, 2016 Business Services, Sales and Marketing Bombay Stock Exchange, Corex, Pfizer Inc, Pfizer Ltd, Shares

Shares in the Indian arm of drug major Pfizer Inc (NYSE: PFE) dropped nearly 8% on the Bombay Stock Exchange …

MSF challenges Pfizer’s pneumonia vaccine patent in India

March 11, 2016 Medical Communications, Research and Development, Sales and Marketing GSK, Pfizer, Prevnar 13, pneumonia vaccine

The charity Médecins Sans Frontières (MSF) has formally opposed Pfizer’s bid to obtain a patent for the pneumonia vaccine PCV13, …
facilities_lg06

Dr. Reddy’s, TR-Pharm to collaborate on 3 biosimilars in Turkey

March 11, 2016 Manufacturing and Production, Medical Communications, Sales and Marketing Dr Reddy's Laboratories, TR-Pharm, biosimilar, generics, marketing collaboration

Three biosimilar products by the Indian generics company Dr. Reddy’s will be marketed by TR-Pharm in Turkey, the companies said …
valeant_sign

US Congress Committee pressures Valeant to produce drug pricing documents

March 11, 2016 Medical Communications, Sales and Marketing Drug pricing, Michael Pearson, Valeant

Valeant’s tough month continued yesterday, with a US congressional committee pressuring the company to explain why it has not produced …

FDA grants approval for first generic version of Viagra

March 10, 2016 Manufacturing and Production, Research and Development, Sales and Marketing FDA, Pfizer, Teva, erectile dysfunction, generic, viagra

The US Food and Drug Administration (FDA) has granted approval to the first generic version of Pfizer’s blockbuster erectile dysfunction …
amarin_logo

Amarin wins case against FDA to promote Vascepa for off-label uses

March 10, 2016 Medical Communications, Research and Development, Sales and Marketing Amarin, FDA, first amendment, off label, vascepa

Amarin has announced a settlement with the US Food and Drug Administration (FDA) that resolves the dispute over the Irish-based …
The Gateway to Local Adoption Series

Latest content